<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Oral Dosage Form New Animal Drugs; Milbemycin Oxime, Lufenuron, and Praziquantel</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Oral Dosage Form New Animal Drugs; Milbemycin Oxime, Lufenuron, and Praziquantel</h1>
    <p class="timestamp">Published: 2012-01-27 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for the veterinary prescription use of milbemycin oxime, lufenuron, and praziquantel for the prevention of heartworm disease, for prevention and control of fleas, and for the treatment and control of various internal parasites in dogs.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Rule</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2012-1744</p>
    <p><strong>Publication Date:</strong> 2012-01-27</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/01/27/2012-1744/oral-dosage-form-new-animal-drugs-milbemycin-oxime-lufenuron-and-praziquantel">https://www.federalregister.gov/documents/2012/01/27/2012-1744/oral-dosage-form-new-animal-drugs-milbemycin-oxime-lufenuron-and-praziquantel</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-1744</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
